Complications of diabetes and obesity

Today, 30% of patients delay the start of insulin treatment, which has led to the facilitation of their access and the promotion of cultural change, according to international health and pharmaceutical organizations.

Obesity is associated with more than 200 complicationsincluding heart disease, diabetes and various types of cancer.

For example, in countries like Mexico, the prevalence obesity in children reaches 40%and if nothing is done, 80% of them will remain obese in their adult life.

Currently, obesity represents up to 10% of all health budget government because of attention to related diseases, with cardiovascular disease being the leading cause of death worldwide, said Martin Lange, executive vice president of development at Novo Nordisk, after celebrating 100 years of progress in diabetes.

“Our heritage has enabled us to understand the unmet needs of patients living with diabetes, obesity and other serious chronic diseases,” said Lars Fruergaard Jørgensen, CEO and Global President of Novo Nordisk.

“Currently, we know that 30% of patients delay starting insulin treatment, which prompted us to facilitate their access and promote cultural change,” he added during a virtual press conference.

progress

“The tools we have today are broader and more powerful than they were 100 years ago. However, there are still many people who struggle to access our products, even though more than 5 million benefit from our access and accessibility initiatives.” reported Martin Lange.’

Obesity accounts for up to 10% of the national health budget due to care for associated diseases, with cardiovascular disease being the leading cause of death worldwide.

Research

The pharmaceutical company is in various stages of research:

– Obesity: CagriSema, a molecule that has the potential to reduce body weight better than Semaglutide, while addressing several cardiovascular risk factors.

– Cardiovascular diseases: Siltivekimab, studies have shown that inflammation plays a key role in atherosclerotic cardiovascular disease.

– Growth hormone deficiency: Somapacitan, this revolutionary treatment allows it to be administered once a week, thus avoiding the need for up to 313 injections per year.